Stockholm, Sweden – Barnik Invest Group, today announced a joint venture partnership with Dynalis Pharma, a renowned Swiss pharmaceutical company, to establish BoniPharmex. This strategic collaboration aims to leverage the combined expertise of both companies to develop and commercialize innovative probiotic and food supplement products.
The company will leverage the expertise of both Dynalis Pharma and StartUpPharma Int. AB to ensure a strong scientific foundation for its products with the highest quality standards and regulatory compliance.
“We are excited to partner with Dynalis Pharma to establish BoniPharmex,” said Hamid Bakhshi, CEO of Barnik Invest Group. “This joint venture aligns with our strategy of investing in innovative product development ventures that have the potential to improve people’s lives. We believe that BoniPharmex will become a leading player in the probiotic and food supplements market.”
For more information, please contact;
Hamid Bakhshi, CEO
Telephone: +46738531165
E-mail: hamid.bakhshi@barnikinvest.com
About Barnik Invest Group
Barnik Invest Group is a leading 360 solution partner for small Life Science companies in the Nordics. The company provides a comprehensive suite of services to support its portfolio companies, including capital, clinical development, expertise, and commercialization. Through its fully-owned subsidiaries, Medicorent and StartUpPharma, Barnik Invest offers CRO services, outsourcing, recruitment, distribution, product development and commercialization solutions. Barnik’s mission is to nurture promising life science companies from early clinical development phase to commercialization, enabling them to achieve positive cash flows or successful exits and ultimately enhancing patient well-being and improving human health worldwide. For more information visit www.barnikinvest.com.
